Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

NCT01514149 · Terminated

Last updated 2026-05-28

This clinical trial tests different doses of the medication CJC-1134-PC in adults with type 2 diabetes who are already taking metformin to see how it affects their blood sugar levels over 18 weeks.

Status Terminated Stopped early and will not restart.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 73 people

Who can join Ages 18–70 · all sexes

Timeline Started 2011-09 · est. completion 2013-03

Where 22 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT01514149 ↗

Description as written by the study sponsor.

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.

Treatments tested

CJC-1134-PC Injection also known as metformin Drug

CJC-1134-PC administered weekly by subcutaneous injection
Weekly placebo for CJC-1134-PC Injection also known as metformin Drug

Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection

Main thing measured	Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18
Sponsor	ConjuChem
Conditions studied	Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01514149 ↗